Idorsia Pharmaceuticals Ltd.
IDIANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for IDIA. That does not mean none is planned.
Get an email about IDIA's next catalysts
Track Idorsia Pharmaceuticals (IDIA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Aprocitentan
Essential Hypertension
Daridorexant
Insomnia Disorder
Cetirizine
Seasonal Allergic Rhinitis
Lucerastat
Fabry Disease
Clazosentan
Aneurysmal Subarachnoid Hemorrhage
tezosentan
Acute Heart Failure
ACT-129968
Seasonal Allergic Rhinitis
ACT-539313
Binge-Eating Disorder
ACT-709478 for oral use
Photosensitive Epilepsy
ACT-541468
Insomnia Disorder
ACT-774312
Bilateral Nasal Polyposis
ACT-280778
Essential Hypertension
Zolpidem
Insomnia Disorder
Setipiprant
Asthma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aprocitentan | Phase 3 | Essential Hypertension | - | - |
Daridorexant | Phase 3 | Insomnia Disorder | - | - |
Cetirizine | Phase 3 | Seasonal Allergic Rhinitis | - | - |
Lucerastat | Phase 3 | Fabry Disease | - | - |
Clazosentan | Phase 3 | Aneurysmal Subarachnoid Hemorrhage | - | - |
tezosentan | Phase 3 | Acute Heart Failure | - | - |
ACT-129968 | Phase 3 | Seasonal Allergic Rhinitis | - | - |
ACT-539313 | Phase 2 | Binge-Eating Disorder | - | - |
ACT-709478 for oral use | Phase 2 | Photosensitive Epilepsy | - | - |
ACT-541468 | Phase 2 | Insomnia Disorder | - | - |
ACT-774312 | Phase 2 | Bilateral Nasal Polyposis | - | - |
ACT-280778 | Phase 2 | Essential Hypertension | - | - |
Zolpidem | Phase 2 | Insomnia Disorder | - | - |
Setipiprant | Phase 2 | Asthma | - | - |
Frequently asked questions
What is in Idorsia Pharmaceuticals Ltd.'s drug pipeline?→
CatalystAlert tracks 14 drug candidates in Idorsia Pharmaceuticals Ltd.'s (IDIA) pipeline across Phase 3, Phase 2. Its lead program is ACT-129968 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Idorsia Pharmaceuticals Ltd.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Idorsia Pharmaceuticals Ltd. (IDIA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IDIA biotech catalysts?→
Add IDIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Idorsia Pharmaceuticals Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.